Commitments and Contingencies - Contingent Consideration (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|
Sep. 17, 2025 |
Sep. 30, 2025 |
Sep. 30, 2025 |
Dec. 31, 2024 |
Apr. 30, 2024 |
|
| Commitments and Contingencies | |||||
| Exarafenib milestone contingent consideration | $ 3,500 | $ 3,500 | $ 3,214 | ||
| Contingent consideration under RPAs, AAAs, and CPPAs | 0 | 0 | $ 3,000 | ||
| HilleVax | |||||
| Commitments and Contingencies | |||||
| Contingent consideration adjustment | $ 5,673 | 5,700 | 5,700 | ||
| Kinnate CVR holders | CVR Agreement | |||||
| Commitments and Contingencies | |||||
| Exarafenib milestone contingent consideration | $ 3,500 | $ 3,500 | $ 3,200 |
| X | ||||||||||
- Definition Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Asset Acquisition, Contingent Value Rights, Consideration Adjustment No definition available.
|
| X | ||||||||||
- Definition Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Classified as current. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|